Showing results (381-390 of 554) with videos related to
Sort By:
Pageof 56
Nature Medicine|June 22, 2019
Publisher Correction: IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.Journal of Virology|April 13, 2018
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea PigsChristine A Bricault, James M Kovacs, Alexander Badamchi-Zadeh, et al.Nature Communications|September 12, 2023
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infectionAdam J Ronk, Nicole M Lloyd, Min Zhang, et al.Nature|November 7, 2018
Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.Science Translational Medicine|September 22, 2017
Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktailBoris Julg, Po-Ting Liu, Kshitij Wagh, et al.Nature Medicine|May 22, 2019
IFN-γ-independent immune markers of Mycobacterium tuberculosis exposureLenette L Lu, Malisa T Smith, Krystle K Q Yu, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.Journal of Virology|March 30, 2005
The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine designMarcus Altfeld, Todd M Allen, Elizabeth T Kalife, et al.Cell Reports|July 21, 2021
An intranasal vaccine durably protects against SARS-CoV-2 variants in miceAhmed O Hassan, Swathi Shrihari, Matthew J Gorman, et al.Nature|October 5, 2018
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysErica N Borducchi, Jinyan Liu, Joseph P Nkolola, et al.Pageof 56